Elutia Inc. Signs Seventh GPO Agreement for EluPro™ Antibiotic Eluting BioEnvelope
Elutia Inc., a leading innovator in drug-eluting biomatrix products, is pleased to announce that it has signed a new agreement with Advantus Health Partners (“Advantus”). This agreement grants Advantus access to Elutia’s EluPro™ Antibiotic Eluting BioEnvelope for inclusion in their core group purchasing organizations (GPO) solutions portfolio.
About Elutia Inc. and EluPro™
Elutia Inc., headquartered in Silver Spring, Maryland, is a pioneering company in the development and commercialization of drug-eluting biomatrix products. Their flagship product, EluPro™, is an antibiotic eluting bioenvelope designed to reduce the risk of surgical site infections (SSIs). EluPro™ is made from a biocompatible material that releases antibiotics over an extended period, providing continuous protection against bacteria.
The Impact on Elutia and Advantus
This agreement represents the seventh GPO contract Elutia has signed since the launch of EluPro™. The partnership with Advantus is expected to expand Elutia’s reach and presence in the healthcare market. Advantus, a leading healthcare services company, will offer EluPro™ to its extensive network of healthcare providers, enabling more patients to benefit from the advanced infection prevention technology.
Global Implications
The signing of this agreement between Elutia and Advantus is a significant step forward in the fight against surgical site infections. According to the Centers for Disease Control and Prevention (CDC), SSIs affect approximately 300,000 patients each year in the United States alone. This number is expected to rise as the population ages and surgical procedures become more common. By providing access to EluPro™ through its GPO solutions, Advantus is helping to make this advanced technology more accessible to healthcare providers and their patients worldwide.
Conclusion
Elutia’s latest agreement with Advantus Health Partners is a testament to the growing recognition and demand for EluPro™ as a leading solution for reducing the risk of surgical site infections. This partnership will allow more healthcare providers to offer their patients the benefits of Elutia’s innovative drug-eluting biomatrix technology. With the global burden of SSIs continuing to grow, this collaboration between Elutia and Advantus is a crucial step towards improving patient outcomes and advancing the field of infection prevention.
